8 results about "Activating mutation" patented technology

The application discloses application of Pemigatinib or a salt thereof in preparation of a medicine, and the compound is used for treating seborrheic keratosis, preferably seborrheic keratosis related to abnormal activation of a fibroblast growth factor receptor (FGFR) signal pathway, but is not limited to the above mechanism, and specifically, the medicine can inhibit or improve skin hyperplasia and hyperkeratosis lesions driven by FGFR3 gene activating mutation.

A compound for use in treating a disease associated with activating mutations in RAS, or for use in treating a disease treatable by a reduction in RAS activity, is selected from a compound of Formula (I), salts and esters thereof. The compounds are particularly useful in treating cancer.

This invention discloses EGFR inhibitors, their preparation, and applications. Specifically, this invention relates to a 4-substituted-2-(N-(5-substituted allylamido)phenyl)amino)pyrimidine derivative of formula (I). This series of compounds exhibits activity against L858R EGFR mutants, T790M EGFR mutants, and exon 19 deletion activation mutants, and can be used to treat diseases mediated by EGFR mutant activity, either alone or in part. For example, they have wide applications in the prevention and treatment of cancer, especially non-small cell lung cancer, and hold promise for development into a new generation of EGFR inhibitors.

To provide methods and compositions for enhancing immune responses against cancer and pathogens.SOLUTION: The presently disclosed subject matter provides methods and compositions for enhancing immune responses against cancer and pathogens. The presently disclosed subject matter relates to cells comprising a c-Kit mutant, e.g., a c-Kit mutant comprising an activating mutation. The cell may further comprise an antigen recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)). The presently disclosed subject matter relates to the use of cells for treatment, e.g., treatment of cancer.SELECTED DRAWING: None

The invention discloses a nucleic acid inhibitor of a targeted thyroid stimulating hormone receptor and application. The nucleic acid inhibitor has high targeting property, and can accurately recognize TSHR and avoid off-target effect; the inhibition effect is strong, and the TSHR function can be obviously blocked under the micro-mole or even nano-mole concentration; as a nucleic acid molecule, the nucleic acid molecule does not cause obvious immune response and is suitable for long-term treatment; good biological stability: after chemical modification, excellent serum stability and tissue penetrating ability are achieved; the compound is suitable for various administration routes, is convenient for clinical transformation, and shows a wide clinical application prospect in treatment of various TSHR-mediated autoimmune and neoplastic diseases such as Graves diseases, thyroid-related eye diseases, TSHR activated mutation-driven thyroid cancer and the like. Especially for moderate and severe TED patients lacking effective specific targeted therapy means at present, the nucleic acid inhibitor is expected to become the first precise therapy for directly intervening the TSHR pathogenic core link.

The present invention provides polypeptides, polynucleotides, constructs and / or vectors comprising activating mutations in 53BP1. In particular, 53BP1 mutation at amino acid position 334 that makes the resulting protein resistant to phosphorylation and inactivation by GSK3β is provided. Also provided are lymphocytes comprising the mutant 53BP1 or a 53BP1 resistant to GSK3β phosphorylation and inactivation and methods of making and using the same.

The invention relates to a compound shown in a formula (I) and an isotope form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a hydrate, a prodrug and a polymorph of the compound, the compound shown in the formula (I) can be used as an EGFR (epidermal growth factor receptor) inhibitor, can effectively inhibit EGFR with L858R mutation, exon 19 deletion mutation, C797S mutation, G724S mutation, L861Q and PACC mutation, and can be used for preparing an EGFR inhibitor. The compound has a good application prospect in the aspect of preparing medicines for treating cancers with EGFR activation mutation.